MOTS-c and longevity: why a mitochondrial peptide has researchers paying attention

The short version: a small peptide your mitochondria make that may help muscles handle fuel.

TL;DR

• MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA.
• Animal research suggests it improves metabolic flexibility and may mimic some effects of exercise.
• It is currently a Category 2 peptide and not available from 503A compounding pharmacies.

What it is

MOTS-c (in plain English: mitochondrial open reading frame of the 12S rRNA-c — a 16-amino-acid peptide encoded by a small piece of mitochondrial DNA) was discovered in 2015 by researchers at the University of Southern California (Lee et al., Cell Metab, 2015). It belongs to a family called mitochondrial-derived peptides (in plain English: tiny peptides made by the mitochondria themselves rather than the cell nucleus). MOTS-c is the most-studied of the family.

How it works

Think of mitochondria as the small power plants inside every cell. MOTS-c is a peptide they release that travels through the bloodstream like a hormone, telling tissues — especially skeletal muscle — to use glucose more efficiently. In mouse studies, MOTS-c administration improved glucose disposal, increased exercise capacity, and reduced age-related insulin resistance (Lee et al., Cell Metab, 2015). The metabolic profile resembles what happens after exercise — which is why some researchers describe MOTS-c as an “exercise mimetic.”

Who asks about it

People ask this when they have heard MOTS-c described in longevity podcasts and want to know what the research actually says. The honest answer: strong animal data, growing human-cell data, very limited human clinical trials so far.

What the research says

The original 2015 Cell Metabolism paper showed MOTS-c administration improved glucose tolerance and prevented age-related insulin resistance in mice. Subsequent work documented MOTS-c levels declining with age in humans and rising in response to exercise (Reynolds et al., Aging Cell, 2018). Human clinical trial data on exogenous MOTS-c administration remains limited compared to the animal literature. The peptide is currently classified as Category 2, meaning it is not available from 503A compounding pharmacies.

What to know before considering it

MOTS-c is not currently accessible through standard compounding channels. The published evidence is primarily preclinical. Any future clinical use will depend on the FDA reclassification process and on human trial data that is still being generated.

The Halftime POV

MOTS-c is the kind of peptide that makes the longevity field exciting and frustrating in the same breath. The biology is novel. The data in humans is thin. We will not prescribe what is not accessible — and we will not pretend animal data is human data.

Related reading:

• MOTS-c: the mitochondria-derived peptide in the literature
• MOTS-c: the mitochondria-derived peptide explained
• Category 1 vs Category 2 peptides: the access framework

FAQ

Q: What is MOTS-c? A: MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, discovered in 2015. It appears to act as a hormone-like signal that influences metabolic flexibility, glucose handling, and exercise response in animal studies.

Q: Is MOTS-c a longevity peptide? A: MOTS-c is studied in the context of metabolic aging and exercise mimicry. It is not currently FDA-approved, and human clinical trial data is limited compared to the animal literature.

Q: Is MOTS-c available from compounding pharmacies? A: MOTS-c is currently a Category 2 peptide, meaning it is not available from 503A compounding pharmacies as of publication date.

Disclaimer

As of April 2026, several peptides discussed in this article — including MOTS-c — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Lee C et al., Cell Metabolism, 2015 — The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis
• Reynolds JC et al., Aging Cell, 2018 — MOTS-c is an exercise-induced mitochondrial-encoded peptide

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.